kabutan

BrightPath Biotherapeutics Co., Ltd.(4594) Summary

4594
TSE Growth
BrightPath Biotherapeutics Co., Ltd.
51
JPY
0
(0.00%)
Dec 5, 11:30 am JST
0.32
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
51.1
Dec 5, 11:18 am JST
Summary Chart Historical News Financial Result
PER
PBR
3.77
Yield
ー%
Margin Trading Ratio
6.24
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
50 JPY 0.32 USD
Previous Close Dec 4
51 JPY 0.32 USD
High Dec 5, 9:05 am
52 JPY 0.33 USD
Low Dec 5, 9:00 am
50 JPY 0.32 USD
Volume
337,300
Trading Value
0.02B JPY 0.11M USD
VWAP
50.84 JPY 0.33 USD
Minimum Trading Value
5,100 JPY 32 USD
Market Cap
5.68B JPY 0.04B USD
Number of Trades
99
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly High
1-Year Average
537
1-Year High Aug 15, 2025
10,957
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 1,405,000 12,452,400 8.86
Nov 21, 2025 1,405,000 13,142,500 9.35
Nov 14, 2025 1,425,100 13,686,800 9.60
Nov 7, 2025 1,421,100 13,865,000 9.76
Oct 31, 2025 1,421,100 14,063,100 9.90
Company Profile
BrightPath Biotherapeutics Co., Ltd. is a biotech venture originating from Kurume University, focusing on cancer immunotherapy using NKT cells and antibody drugs.
Sector
Pharmaceuticals
BrightPath Biotherapeutics Co., Ltd. is a drug discovery venture specializing in the development of cancer immunotherapy drugs, originating from Kurume University. The company has multiple pipelines ranging from exploratory research to early clinical trial stages, with a business model that generates revenue by licensing out to domestic and international pharmaceutical companies for late-stage clinical trials and beyond. Major development pipelines include iPS cell-derived NKT cell therapy, CAR-T cell therapy, antibody drugs, and personalized neoantigen vaccines. Notably, in the field of iPS cell-derived NKT cell therapy, the company exercised its option rights in November 2022 to acquire an exclusive development, manufacturing, and sales license from RIKEN, and is conducting the world's first clinical trial using iPS-NKT cells for head and neck cancer. Additionally, the company is advancing the development of CAR-T cell therapy for solid tumors. BrightPath Biotherapeutics is also developing antibody drugs targeting molecules that suppress cancer immunity, aiming to innovate cancer treatment through multiple approaches.